1 An *ex vivo* cystic fibrosis model recapitulates key clinical aspects of

2 chronic *Staphylococcus aureus* infection.

3

4 Esther Sweeney[1*], Niamh E. Harrington[1], Marwa M. Hassan[1,2], Alicia G. Harley-

5 Henriques[1], Branagh. Crealock-Ashurst[1], Alan R. Smyth[3], Matthew N. Hurley[4], María

6 Ángeles Tormo-Mas[5], Freya Harrison[1*]

7

8 [1]School of Life Sciences, University of Warwick, Coventry, CV4 7AL, United

9 Kingdom

10 [2]Department of Pathology and Infectious Diseases, School of Veterinary Medicine,

11 University of Surrey, Guildford, United Kingdom

12 [3]Division of Child Health, Obstetrics and Gynecology, Queen's Medical Centre,

13 University of Nottingham, Nottingham NG7 2UH, United Kingdom

14 [4]Paediatric Respiratory Medicine, Nottingham Children's Hospital, Queen's Medical

15 Centre, University of Nottingham, Nottingham NG7 2UH, United Kingdom

16 [5]Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell, 106

17 Torre A Lab. 6.13. 46026 Valencia, Spain.

18

19 *Corresponding Authors: e.sweeney@warwick.ac.uk, f.harrison@warwick.ac.uk

20

Abstract

Staphylococcus aureus is the most prevalent organism isolated from the airways of people with cystic fibrosis (CF), predominantly early in life. Yet its role in the pathology of lung disease is poorly understood. In mice, and many experiments using cell lines, the bacterium invades cells or interstitium, and forms abscesses. This is at odds with the limited available clinical data: interstitial bacteria are rare in CF biopsies and abscesses are highly unusual. Bacteria instead appear to localise in mucus plugs in the lumens of bronchioles. We show that, in an established *ex vivo* model of CF infection comprising porcine bronchiolar tissue and synthetic mucus, *S. aureus* demonstrates clinically significant characteristics including colonisation of the airway lumen, with preferential localisation as multicellular aggregates in mucus, initiation of a small colony variant phenotype and increased antibiotic tolerance of tissue-associated aggregates. Tissue invasion and abscesses were not observed. Our results may inform ongoing debates relating to clinical responses to *S. aureus* in people with CF.

Impact Statement

Chronic bacterial infection is one of the main causes of declining lung function and morbidity in people with cystic fibrosis (CF). *Staphylococcus aureus* is the most prevalent organism isolated from airways of infants with CF. Yet its overall role in the pathogenesis of pulmonary disease is poorly understood. More accurate, high throughput models of CF lung infection are necessary to explore the interactions between *S. aureus* and host in this context. *In vitro* studies cannot accurately replicate chronic disease characteristics, such as presence of small colony variants, and animal models also do not represent features of clinical disease. Mice, in particular, are not

49 readily colonised by *S. aureus* and when infection is established it leads to the

50 formation of abscess, a phenomenon not observed in the human CF lung. Here we

51 show an existing *ex vivo* pig lung model of CF infection supports growth of *S. aureus*

52 and that *S. aureus* demonstrates clinically significant characteristics including

53 appearance of small colony variants, increased antibiotic tolerance and preferential

54 growth as aggregates in mucus.

55

56 **Data summary**

57 The authors confirm all supporting data, code and protocols have been provided within

58 the article or through supplementary data files.

59

60 **Introduction**

61

62 *Staphylococcus aureus* (*S. aureus*) is currently the most prevalent pathogen isolated

63 from the airways of people with cystic fibrosis (CF) (1). Historically, it is has been

64 associated predominantly with paediatric pulmonary infection (2) yet most recent data

65 shows that ~50% of even the oldest patients are now colonised (3). The presence of

66 *S. aureus* in the respiratory tract varies considerably geographically and over time,

67 and although prevalence appears to decrease with age (4) MRSA is most prevalent

68 between 10-30 year olds(3). Determining the difference between colonisation and

69 infection is both important and difficult. Nasal carriage of *S. aureus* among children

70 with cystic fibrosis is common: Stone *et al.* (5) reported that 52.4% of the infants they

71 studied harboured the organism. However, relatively high carriage rates in healthy

72 children have also been recorded (6). Further, expectorate is difficult to collect from

73 infants, so samples are usually collected by oropharyngeal swab, but presence of

74 organisms in the upper respiratory tract is not always indicative of lower airway

75 infection (7, 8).

76

77 Moreover, the association of *S. aureus* with progressive lung disease – as measured

78 by worsening lung function and the development of subsequent infection by the

79 chronic CF pathogen *Pseudomonas aeruginosa* – is unclear (9). *S. aureus* is able to

80 rapidly adapt to and persist in the CF lung environment (10), and worsening lung

81 condition has been associated with the formation of *S. aureus* small colony variants

82 (SCVs) (11). SCVs are known to remain in the lung longer than wild type (WT)

83 bacterial cells (12) and demonstrate increased antimicrobial resistance (13). In

84 studies of bronchoalveolar lavage (BAL) fluid from children aged 0-7 years, both

85 Gangell *et al.* and Sagel *et al.* (14, 15) found that positive *S. aureus* culture was linked

86 to a higher degree of airway inflammation, as measured by increased neutrophil count

87 and IL-8. In another study, lung damage (bronchiectasis) in early CF was recorded by

88 CT scan and *S. aureus* was the most commonly isolated organism (16). Conversely,

89 in adult CF patients, *S. aureus* infections, in the absence of *P. aeruginosa,* are a

90 marker of milder disease (1). There is also an indication that methicillin sensitive *S.*

91 *aureus* may inhibit *P. aeruginosa*, thus delaying lung disease progression (17). The

92 evidence that early *S. aureus* infection worsens prognosis for CF patients remains

93 conflicting and warrants further study (3)(18).

94

95 The lack of understanding regarding the role of *S. aureus* in the development of lung

96 disease in CF has led to debate over the use of anti-staphylococcal prophylaxis early

97 in life. Studies by Ratjen *et al.* and Stutman *et al.* (19, 20) linked the use of broad-

98 spectrum antibiotics to an increase in *P. aeruginosa* isolation. However, a recent

99 Cochrane review (21) showed no effect of anti-staphylococcal prophylaxis on *P.*

100 *aeruginosa* colonisation at 3-4 years. There was a suggested trend towards higher

101 rates of *P. aeruginosa* at 4-6 years but as the studies reviewed did not last more than

102 six years, conclusions about the long-term effects of prophylaxis could not be drawn.

103 A pragmatic randomized controlled trial is currently in progress

104 (http://www.cfstart.org.uk).

105

106 In addition to the lack of clarity over the clinical consequences of *S. aureus* colonisation,

107 there is also a gap in our mechanistic understanding of the microbiology of *S. aureus* in

108 CF. The interaction of *S. aureus* with the pulmonary airway in CF, and its subsequent role

109 in pathogenesis, is not clearly documented. CF epithelial cells have been shown to have

110 an increased abundance of aGM1, a receptor that binds *S. aureus* and *P. aeruginosa*,

111 compared with wild-type epithelia (22), and an *in vitro* study by Schwab *et al.*

112 demonstrated that bacterial adherence to a bronchial epithelial cell line was significantly

113 greater for CF *S. aureus* isolates than non-CF (23). McKenney *et al.* also show aggregates

114 of *S. aureus* are visible on the surfaces of bronchial sections from children with CF (24).

115 Yet, the only other study we found with direct evidence of *S. aureus* infection in human

116 biopsy specimens, demonstrated that *S. aureus* did not adhere to the airway epithelium

117 but was found aggregating within the mucus (25). Furthermore, these authors cited

118 several studies reporting an ability of *S. aureus* to bind mucins (26, 27). It is obvious that

119 better understanding of just how *S. aureus* colonizes the airway in CF is required, as are

120 unambiguous data on the underlying mechanisms of pathogenesis and virulence, and the

121 influence of *S. aureus* on subsequent infection by other microorganisms.

122

123   Mice are the most commonly used animal model of pulmonary infection in CF. Mouse

124   models have been used to identify virulence-related genes in pathogens and to test

125   novel therapeutic agents aimed at reducing inflammation or infection (28). However,

126   mouse models present a number of challenges. In particular, mice do not develop

127   spontaneous *P. aeruginosa* endobronchial infection, suppurative lung disease and

128   mucus plugging of the airways, that are fundamental characteristics of human CF

129   progression (29). *S. aureus* does not appear to readily colonize the airways of mice or

130   produce an inflammatory response, even when clinical strains are used, in the

131   presence of mucus (30). Furthermore, *S. aureus* forms severe abscess-like lesions in

132   the mouse lung (31). When lung abscess does occur in humans, *S. aureus* is the most

133   commonly isolated organism (32). However, lung abscess is rare in children (33) and

134   even more so in people with CF: since the advent of neonatal screening and survival

135   past infancy, abscesses are almost never observed in the CF population (34-36).

136

137   We previously developed a clinically relevant, high throughput model of chronic bacterial

138   infection in CF. By combining sections of porcine bronchiole (obtained post-slaughter

139   from a commercial abattoir) with culture medium which mimics CF sputum (artificial

140   sputum medium, ASM (37)) we have shown that we can study another key CF pathogen,

141   *P. aeruginosa,* in a physicochemical environment similar to that present *in vivo* (38-40).

142   The use of CF-like growth medium combined with animal tissue with a greater structural,

143   chemical and immunological similarity to human lung (41) means that our model is likely

144   to facilitate a more human-like pathology of *S. aureus* than that observed in mouse models

145   or *in vitro* studies. Using clinical reference strains and CF isolates of *S. aureus,* we can

146   now demonstrate that in a CF-like environment, *S. aureus* shows non-invasive pathology.

147   Bacteria grow as aggregates associated with the surface of bronchioles and in the

surrounding artificial sputum, without the formation of abscesses or other significant ultrastructural changes to tissue. In fact, we report a potential preference for aggregation in the surrounding mucus rather than growth associated with the bronchiolar surface. We also report the appearance of sub-populations of SCVs. Our work is consistent with *S. aureus* adopting a "persister" rather than "invader" strategy in CF. This stands in marked contrast to the pathology of this species in mouse and cell culture infection models, and underlines the importance of selecting models that reflect host-pathogen interactions more closely, in order to reliably study the role of specific bacteria in clinical disease progression. A better understanding of *S. aureus* pathology in the highly idiosyncratic environment of the CF lungs will inform optimised clinical responses to positive *S. aureus* cultures.

Materials and Methods

Bacterial strains. USA300 Los Angeles County clone (JE2, BEI resources) was used as an example of a well-documented clinical strain. 18 *S. aureus* stains isolated from 9 people with CF at Hospital Universitari i Politecnic La Fe were included as exemplars of CF associated strains. The strains used in this work were extracted for diagnostic purposes and sent to the microbiology service for routine analysis. Once analyzed, and instead of being discarded as usual, the strains were grown in tryptic soy broth and kept in glycerin. We chose isolates that represented a range of patient clinical presentation and bacterial phenotypes (e.g. weak or strong biofilm formation as measured by *in vitro* attachment assays, and isolates from patients during periods of stable presentation and episodes of acute exacerbation) (See Table S1).

Media and culture conditions for growth in the *ex vivo* pig lung (EVPL) model.

For use in the lung model, bacterial stocks were grown overnight at 37 °C on lysogeny broth (LB) agar. Artificial sputum medium (ASM) was prepared according to Palmer *et al.* (37) with the modification that we removed glucose and supplemented with 20 µg ml^{-1} ampicillin. Our previous work suggested that glucose facilitated the growth of endogenous bacteria present in the lungs and that ampicillin helped to limit the growth of any resident bacteria in the lung that remained after sterilisation (38). We selected a concentration of ampicillin that provided the best possible coverage against endogenous populations but was sub-inhibitory for the *S. aureus* strains used (confirmed by standard MIC testing at the time of collection).

The EVPL model was adapted from our group's previous work (38, 39), which in turn built on prior use of pig lungs for non-CF studies (42). Briefly, lungs were collected from a local butcher (Steve Quigley and Sons, Cubbington, Warwickshire) as soon as possible following abattoir delivery, and processed immediately upon arrival at the laboratory. Previous antibiotic administration history of the pigs is not known, but use of antibiotics as growth promoters is banned in the EU, so use is restricted to prophylaxis and mass medication of herds only when infection is suspected. Approximately 5mm^2 sections of bronchiolar tissue were dissected from the lung under sterile conditions. During dissection the sections were washed three times with a 1:1 mix of RPMI 1640 and Dulbecco's modified Eagle medium (DMEM) (Sigma-Aldrich), supplemented with 50 µg ml^{-1} ampicillin, and then rinsed once in sterile ASM without ampicillin supplementation. Bronchiolar samples were transferred to a clean petri dish and sterilized under a UV lamp for 5 minutes. Previous work has shown that tissue damage as a result of UV sterilisation is minimal (not visible using light microscopy)

198 (39). Samples were transferred to 24-well tissue culture plates: each well contained

199 400 µl ASM supplemented with 0.8 % w/v agarose to form a soft pad. Tissues were

200 inoculated with the appropriate strain of bacteria using a sterile hypodermic needle

201 (29G). The tip of the needle was lightly touched to the surface of the chosen *S. aureus*

202 colony, and then used to pierce the surface of bronchiolar tissue for inoculation. A

203 sterile needle was used for mock infection in uninfected controls. 500 µl of ASM + 20

204 µg ml^{-1} ampicillin was added to each well and the plate was sealed with a Breath-

205 Easier membrane (Diversified Biotech). Plates were incubated at 37 °C for up to 7

206 days and refreshed with 300 µl of ASM + 20 µg ml^{-1} ampicillin at 48 h. Following

207 incubation, tissue was rinsed in 1 ml phosphate-buffered saline (PBS) to remove

208 loosely adhering cells and processed for colony counts and microscopy.

209

210 **Bacterial load assay.** Tissue samples used to assay total bacterial numbers in tissue-

211 associated biofilm were homogenised individually in 1ml PBS in reinforced metal bead

212 tubes (Fisherbrand) using a FASTPREP 24 5G homogenizer (MP Biomedicals) for 40

213 sec at 4.0m sec^{-1}. Homogenates were serially diluted and aliquots were plated on LB

214 and mannitol salt (MSA) agar (Oxoid, Thermo Scientific) to obtain single colonies.

215 MSA agar is selective for *Staphylococcus* and was used to determine colony numbers

216 of test strains and ensure that negative controls did not contain any *S. aureus* already

217 resident in the lung tissue prior to experimentation. Non-selective LB agar was used

218 to check for contamination or growth of endogenous populations. When bacterial load

219 in ASM surrounding the lung tissue was measured, 300 µl of ASM was taken from

220 each well at the same time as tissue processing and transferred to a sterile Eppendorf

221 tube. Samples were vortexed, serially diluted and plated in the same way as tissue

222 homogenate.

223 LB plates were incubated aerobically at 37 °C for 18-24 h and MSA plates were

224 incubated in at 37 °C 5% CO_2 for 24 h and then for an additional 48 h at room

225 temperature in ambient CO_2 to allow visualisation of slow growing colonies. Total

226 numbers of *S. aureus* recovered from the complete sample were calculated from

227 tissue and ASM colony numbers combined.

228

229 **Microscopy.** Replica 5mm^2 bronchiolar tissue samples, dissected and inoculated as

230 above, were preserved for hematoxylin and eosin staining. Samples were placed in

231 individual tissue processing cassettes (Simport) and fixed overnight in 10% neutral

232 buffered formalin (NBF) at approximately 20 times w/v. Longitudinal, step sections

233 (100μm) were prepared for histopathology by an external service (University of

234 Manchester). If samples required storage before transport, they were placed in 70%

235 ethanol and kept at 4°C for up to 7 days. Sections were transported in PBS with

236 residual NBF. In addition, 10 µl samples were taken from the ASM surrounding lung

237 tissue, diluted 1:10 in PBS and 5 µl drops prepared for gram stain.

238 Microscopy was conducted with an Axio scope.A1 light microscope (Carl Zeiss) with

239 AxioCam ERc5S digital camera and images processed in Zen Pro 2.1 Blue edition.

240

241 **Colony identification.** Colonies that were able to grow on MSA plates and ferment

242 mannitol (indicated by yellow pigmentation of colony and surrounding clear zone) were

243 regarded as *S. aureus*. Colony morphology was recorded by digital photography. The

244 identity of colonies that were weak fermenters or small in size was initially confirmed

245 using hydrogen peroxide to test for the production of catalase and a staphylase assay

246 (Oxoid). If SCVs were suspected, colonies were recovered by aerobic incubation

247 overnight on Columbia Blood Agar and morphology was compared to the originally

248 inoculated parent strain. PCR of large and small colonies from MSA plates was used

249 to verify taxonomic identity. First, we performed colony PCR using *Staphylococcus*-

250 specific primers (43). Once genus was confirmed, amplification of the 16S-23S rRNA

251 intergenic spacer region and Sanger sequencing was used to confirm that SCVs were

252 *S. aureus* (primers 5'-TGCCAAGGCATCCACCG-3' and 5'-

253 GGCTGGATCACCTCCTT-3').

254

255 **Determination of antibiotic susceptibility by microdilution**. The minimium

256 inhibitory concentration (MIC) of Flucloxacillin against a pair of representative MSSA

257 isolates (FQ128 and FQ142) and the standard MSSA control strain, ATCC29213, was

258 determined according to the british society of antimicrobial chemotherapy guidelines

259 for microdilution (44) before examining antibiotic tolerance in the EVPL model. All

260 isolates were from sputum samples collected from people with CF during stable

261 presentation. All three strains demonstrated an MIC of <0.0625mg/l and were sensitive

262 to flucloxacillin.

263

264 **Antibiotic tolerance in the EVPL model.** Infected lung bronchioles incubated for 48

265 h as described above. At 48 h 'pre-dose' tissue samples were homogenized and

266 assayed as above. Biological replicates (4 bronchiolar sections for each strain and

267 condition) were challenged with antibiotic: tissue samples were washed in PBS then

268 placed in a new 24 well plate on agar pads. 500µl ASM alone was added for controls

269 and 500µl ASM + either 0.25mg/l or 5mg/l flucloxacillin for antibiotic tolerance test

270 samples. Concentrations were calculated from the recorded broth MIC of < 0.0625mg/l

271 for the strains tested and the clinical target pharmacokinetic (PK) parameters. The PK

272 parameter for beta lactam efficacy is T>MIC with a target of 50% of dosing interval at

273 a free plasma concentration 4-5 x MIC (45). 5mg/l was included to account for potential

274 protein binding, which is 95% for Flucloxacillin (46). Plates were incubated at 37 °C.

275 At 4 and 24 H post dose, treated tissues were washed in PBS to prevent any antibiotic

276 carryover, and all samples homogenised and plated as described above. The bacterial

277 loads in non-antibiotic and antibiotic treated tissues were compared.

278

279 **Statistical analysis** All data were analysed using RStudio (Mac OS X 10.6+ version

280 1.0.153) (RStudio, https://www.rstudio.com) using linear models followed by ANOVA

281 and post-hoc Tukey HSD tests where appropriate, or using Kruskall-Wallis tests, as

282 specified in the text.

283

284 **Results**

285

286 **Clinical strains of *Staphylococcus aureus* are able to colonise EPVL.** Data taken

287 from preliminary experiments (Fig 1) showed that bacterial load (CFU) recovered at

288 48 h was similar for a large range of *S. aureus* CF clinical isolates, and comparable to

289 Los Angeles County clone of USA300, a methicillin resistant (MRSA) clinical isolate

290 known to form biofilm (47). Table S1 shows details of CF isolates. Samples were taken

291 from people presenting either with acute exacerbation or in a stable condition (defined

292 as chronic isolates). Isolates were grouped randomly and tested on three separate

293 occasions. In each case lung samples were dissected from a single lung. Differences

294 in growth were distinguishable between strains (ANOVA. $F_{2,40} = 1.9$, $p = 0.02$) but post

295 hoc analyses showed no significant difference between any CF isolate and

296 USA300LAC (see supplementary data). The median values for *S. aureus* load

297 recovered at 48 h were 1.64×10^5, 3.64×10^5 and 6.1×10^5 CFU respectively for lungs 1-

298 3. Growth on Staphylococcal selective media (MSA) was only observed on one of the

299 uninfected controls (Fig 1, Panel A).

300

301 **_S. aureus_ growth in association with bronchiolar tissue depends on strain and**

302 **lung but trends are consistent overtime.** To verify the reproducibility of _S. aureus_

303 numbers recovered from bronchiolar tissue and the ability to observe differences

304 between strains, triplicate samples of USA300LAC and two clinical strains were

305 inoculated into three further lungs taken from different pigs (Fig 2) and incubation was

306 extended to 7 days. Clinical isolate FQ151 was compared with FQ184, these strains

307 were chosen as an appropriate example pair as they were both isolated from patients

308 with similar demographics, both MRSAs that form biofilm, and had both demonstrated

309 comparable rates of recovery at 48 h from the same lung (Fig 1). However, FQ184

310 was isolated during an acute disease exacerbation and FQ151 during stable

311 presentation (representing chronic infection or colonisation) (Table S1). It was

312 therefore hypothesised, that by comparing these two strains, differences between

313 exacerbation-associated strains and those apparently persisting asymptomatically

314 may be observed, and, if so, could be further investigated with a larger selection of

315 paired isolates. Figure 2 shows that USA300 was again able to establish in the lung

316 and mean _S. aureus_ load recovered at 48 h was 6.8×10^6 CFU. Mean yields for clinical

317 strains at 48 h were 3.8×10^6 and 5.5×10^5 CFU for FQ184 and FQ151, respectively. By

318 7 days no colonies were recovered from tissue taken from one of the three lungs for

319 either clinical strain, and counts for clinical strains in a second lung were below or

320 close to the lower limit of detection. Average CFU counts at day 7 were 4.2×10^3 for

321 USA300, 7.9×10^3 for FQ184 and 8.1×10^3 for FQ151. The data were analysed by

322 ANOVA to test for differences between strains, lungs and days, and interactions

323 between day*lung and strain*lung. Total bacterial load was significantly different once

324 again between strains ($F_{2,40} = 12.0$, $p < 0.001$) and between lungs ($F_{2,40} = 6.03$, $p =$

325 0.005). There was a main effect of day ($F_{1,40} = 155$, $p < 0.001$) and the magnitude of

326 the drop between 48 h and 7 days did not vary significantly between lungs (day*lung

327 interaction $F_{2,40} = 9.5$, $p = 0.110$) or between strains (strain*day interaction $F_{2,40} = 1.73$,

328 $p = 0.190$). Different lungs did, however, affect the growth of the strains differently

329 (lung*strain interaction $F_{4,40} = 2.62$, $p = 0.049$).

330

331 **_S. aureus_ is visible as aggregates at the airway-tissue interface but does not**

332 **appear to invade tissue.** Monitoring bacterial load within the model by CFU count

333 shows that the model can maintain a _S. aureus_ population at 48 h. In addition, it was

334 important to investigate whether the consistent decline in CFU counts by 7 days was

335 due to the inability of the model to support _S. aureus_ or whether adaptation of _S._

336 _aureus_ within the model prevented sufficient monitoring, for example if cells were

337 growing in strongly adherent biofilm that had not been washed off, or as SCV or

338 persister cells that were difficult to recover on media. Therefore, samples were

339 histologically examined to gain a better understanding of growth characteristics in the

340 model. Samples of the inoculated lung tissue (dissected from bronchi for original

341 model) were washed in PBS and prepared for microscopy, by longitudinal, step section

342 (100μm), at 2 and 7 days post infection. Histopathological staining (Figure 3 and 4)

343 showed bronchial mucosa, represented by mature cartilage. In infected samples there

344 is clear evidence of polymorphs and organisms, including, predominantly gram

345 positive bacilli. Polymorphs and organisms are largely absent from uninfected controls

346 with the exception of a small number of rod shape organisms (fig 3b). Gram positive

347   bacilli aggregate primarily at the tissue airway interface of infected lungs and their

348   absence from the uninfected lung, (Figs 3a, 3b and 4a, 4b) strongly suggests that they

349   are the *S. aureus* deliberately inoculated into test samples. Lung tissue remained

350   largely intact across all tested isolates, even at 7 days. There was some disruption of

351   tissue integrity at the surface, illustrated by the presence of fibrinous material

352   (highlighted with *). None of the samples show any evidence of abscess, which would

353   present as a clearly-defined, bordered structure. *S. aureus* is present only at the

354   tissue-airway interface and does not appear to demonstrate tight association with

355   tissue in the form of a mature biofilm, although more specific staining for biofilm would

356   be required to confirm this.

357

358   Evidence of other organisms in some samples, for example rod shaped cells in the

359   tissue infected with FQ184 at 48 h (arrow, Fig 3f, 100x magnification), is likely to be

360   endogenous populations present prior to dissection (healthy lungs are not sterile) or

361   contaminants not removed during sterilisation; they are also present in the uninfected

362   control (arrow, Fig 3b). Interestingly, when other bacteria are present, there appear to

363   be distinct ecological niches within the lung environment with gram positive bacilli

364   clustered primarily at or near the surface, and rods present embedded within smooth

365   muscle and connective tissue. This supports much of the current understanding of the

366   structural architecture of polymicrobial communities and it would be useful to study

367   this further especially as the presence of other bacteria may affect the ability of *S.*

368   *aureus* to survive and adapt within the model. By day 7, cells in clusters of FQ151

369   were small and poorly stained, and thus difficult to image (Fig 4d). This may indicate

370   the cells are no longer viable and explain the lack of colonies recovered on plates (Fig

371   2). Although inconclusive, the images appear to suggest that there is still a presence

372   of bacterial cocci in association with the lung tissue at 7 days post inoculation, despite

373   poor recovery of colonies on selective media. It highlights that sputum sampling and

374   colony count alone cannot reliably determine the presence of *S. aureus* populations

375   that may be viable but non-culturable. It would be useful to further investigate, perhaps

376   with the use of Staphylococcus aureus specific fluorescent probes or live dead staining

377   in order to confirm the identity and viability of the cells.

378

379   ***S. aureus* aggregates in artificial sputum surrounding lung tissue.** Initial

380   experiments (Figs 1, 2) only recorded bacterial burden recovered from washed tissue

381   pieces. The histology suggests at least some *S. aureus* may be tightly associated with

382   the tissue in the model and not removed during homongenisation. In addition, there is

383   evidence in the literature to suggest *S. aureus* may preferentially bind to mucus plugs

384   in the airways of the CF lung, rather than associating with the tissue surface (25). Both

385   are possible explanations as to why, despite presumably being adapted to the lung

386   environment, CFU loads associated specifically with the bronchiolar tissue showed

387   such a marked drop by day 7.

388

389   A subset of clinical strains, two MRSA and two MSSA (methicillin sensitive) strains,

390   were chosen to investigate growth in the surrounding ASM, and compared with

391   USA300 (Fig 5). When bacteria were also recovered from the surrounding ASM and

392   enumerated, the total CFU count from the sample (tissue plus surrounding ASM) was

393   higher than the CFU count for tissue only (Fig 5a). Although 'mucus plugs' do not form

394   in the model, aggregates of *S. aureus* cells were visible in Gram stains of surrounding

395   ASM at day 7 for all strains tested (Fig S5) and by day 7, a greater proportion of the

396   total bacterial population was consistently found in the surrounding ASM than in tissue-

397   associated biofilm (Fig 5b). The four biofilm forming strains all showed a significant

398   increase in the proportion of recoverable cells in the ASM between 48 h and day 7 as

399   measured by the Kruskal Wallis Test (FQ128 χ^2_1 = 7.44, FQ140 χ^2_1 = 11, FQ151 χ^2_1 =

400   7.1, USA300 χ^2_1 = 12.3; all p-values ≤ 0.008). FQ142 did not show a significant

401   increase in ASM proportion between the two time points (Kruskal Wallis test, χ^2_1 = 1.2,

402   p = 0.22). As FQ142 is not a biofilm former (Table S1), this is likely due to a higher

403   proportion already in the ASM by 48 h. ASM is a minimal media and it is significant

404   that there are viable cells are maintained in the ASM for 7 days with limited nutrient

405   replenishment, suggesting the addition of lung tissue to the model is an important

406   improvement.

407

408   **Tissue associated populations demonstrate phenotypes consistent with**

409   **chronic infection.** The data collected by cell enumeration (Figs 1, 2 and 5), for growth

410   and localisation of *S. aureus* in the model, suggest the existence of subpopulations

411   present during chronic infection. These likely comprise aggregates of cells in the

412   mucus and a smaller percentage of tissue or biofilm associated cells, which may be

413   slow growing SCVs or non-growing persisters. If this is the case it would be consistent

414   with hypotheses in the literature regarding *S. aureus* infection(48), and we would

415   anticipate that there would be SCVs present in the model and the "persister"

416   subpopulation would demonstrate increased antibiotic tolerance.

417
418   Small colonies (<50% diameter of usual *S. aureus* colonies) were observed on MSA

419   plates after incubation for at least 48 h in 5% CO_2 at 37 °C for samples taken 7 days

420   post inoculation. Example colonies were photographed (Fig S6) and some had weak

421   catalase and coagulase results when tested, weak catalase is indicative of deficient

422   heme production and associated with SCVs, as is weak coagulase. SCVs were

423   confirmed as *S. aureus* spp. using genus-specific primers (STaG) (43) followed by

424   sequencing of the 16s-23S intergenic region (Table S2).

425

426   **Antibiotic tolerance of tissue associated aggregates.**

427

428   Slow growing or biofilm bacterial populations may be tolerant to antibiotics and

429   implicated in the persistence of chronic infection. Tolerance of tissue associated

430   aggregates to flucloxacillin was assessed for a pair of clinically isolated MSSAs that

431   were susceptible to flucloxacillin in a standard MIC microdilution and had the same

432   MIC as the control strain ATCC29213 (<0.0625mg/l). They were isolated from people

433   who presented asymptomatically (without exacerbation) (Table S1). Lung tissue was

434   infected with *S. aureus* and incubated as described above. At 48 h, antibiotic test

435   samples were challenged with a single dose of either 0.25mg/l or 5mg/l (to account for

436   potential protein binding) flucloxacillin; control samples were maintained in ASM alone.

437   Tissue was processed at 4 and 24 h post dose and total *S. aureus* load recorded as

438   before (Fig 6a). As in previous experiments, uninfected control tissues showed no

439   growth on MSA plates. Clinically, bactericidal activity of an antibiotic is regarded as a

440   reduction of 99.9% (>3 $\log_{10}$ decrease) in the CFU/ml of the original sample. The data

441   presented in Fig 6b demonstrates that a mean decrease of >3 $\log_{10}$ was only achieved

442   against FQ142 when challenged with the higher concentration of 5mg/l flucloxacillin

443   for 24 h, despite all three strains demonstrating susceptibility in a standard MIC test.

444   For ATCC29213 there was no significant effect of dose (ANOVA, $f_{2,21}=0.2$ $p=0.8$) or

445   dosing interval (ANOVA, $f_{2,21}=1.9$ $p=0.2$) on CFU/ml. Although there was an overall

446   significant effect of dose on CFU/ml for FQ128 (ANOVA, $f_{2,21}=5.8$, $p=0.01$) and FQ142

447   (ANOVA, $f_{2,21}=7.5$, $p=0.004$), post-hoc analysis showed this was not significant for

448   0.25mg/l (FQ128, p=0.8 and FQ142, p=0.2) and a mean decrease in CFU/ml of

449   >3$\log_{10}$ was not achieved for either strain at this concentration (Fig 6b). Dosing interval

450   was found to be significant for FQ128 ($f_{2,21}$=7.2, p=0.004) but not for FQ142 ($f_{2,21}$

451   =0.03, p=0.97). The fact that the required bactericidal target was not reached for the

452   control strain, ATCC29213, and that the response of the two clinical isolates varied,

453   shows that standard MIC testing may not reliably predict clinical response to antibiotic

454   regimes. There was no significant decrease in bacterial recovery between pre-dose

455   and 24 h post dose when challenged with 0.25mg/l flucloxacillin and FQ142 showed

456   a potential to grow under these conditions, suggesting sub-inhibitory flucloxacillin

457   concentrations could lead to the development of resistance. Furthermore, although

458   5mg/l flucloxacillin had a significant effect on CFU/ml for both clinical strains, it failed

459   to cause a mean decrease in FQ128 CFU/ml of >3$\log_{10}$, suggesting that some strains

460   could tolerate clinically relevant concentrations even when antibiotic protein binding is

461   accounted for. This was a very small sample set, and further investigation is

462   warranted, but, it indicates that maintaining plasma concentrations well above the

463   target of 4 x MIC maybe necessary for effective treatment of *S. aureus* infection in CF.

464

465   **Discussion**

466

467   **Growth and localization of *S. aureus* in EPVL.** There is an apparent contradiction

468   between the usual pathology of *S. aureus* in human CF samples (non-invasive) and in

469   standard laboratory models using cell culture or mouse lung infections. To address this

470   gap between the clinical norm and standard lab models, we grew a biobank of clinical

471   isolates in an *ex vivo* model of CF lung infection which carefully mimics human tissue

472   structure and the chemistry of CF lung secretions. *S. aureus* grew with reasonable

473 consistency, both associated with lung tissue, at the airway surface, and as bacterial

474 aggregates in artificial sputum (ASM) around the tissue. *S. aureus* bioburden was

475 maintained in EPVL over 7 days, although tissue-associated CFU numbers were

476 diminished over this period and in general the bacteria showed a preference for growth

477 as aggregates suspended in the ASM.

478

479 Defined biofilm was not investigated in histological samples, although there was evidence

480 of potential biofilm architecture and increased structure in bacterial populations for some

481 samples by 7 days compared to 48 h. Interestingly, we have recently reported that

482 *Pseudomonas aeruginosa* does demonstrate extensive biofilm growth in the EPVL that

483 can be observed using the same histological staining techniques (40). This is consistent

484 with the available clinical evidence where extensive biofilms have not been described for

485 *S. aureus* in the CF lung (49), but small, biofilm-like aggregates are reported in the sputum

486 and on the surface of airways (24, 25, 50, 51). Consistent with growth as aggregates *in*

487 *vivo*, there is evidence that *S. aureus* switches off the global regulator *agr* in CF (48).

488

489 We did not observe interstitial invasion by *S. aureus*. Generally, interstitial bacteria are

490 rarely observed in biopsy samples from people with CF (even if significant interstitial

491 inflammation is observed) and bacteria in the airways are confined in luminal mucus plugs

492 or occasionally attached to defined foci of epithelial erosion; this lack of tissue invasion is

493 consistent with the rarity of bacteremia in people with CF (24, 25, 52-57). CF lung disease

494 thus presents as bronchiectasis with mucous plugging of small airways. In contrast,

495 microscopy images presented in studies of murine pulmonary *S. aureus* infections

496 typically show abscesses (a cavitating, pus-filled lesion within the tissue with a defined

497 border: see Figure 2 in (31) and Figure 2 in (58), for examples) and lead to chronic

498   pneumonia (59). Clearly, there are significant differences in *S. aureus* pathology in mouse

499   models *versus* the highly specialised environment of CF airways as approximated by the

500   *ex vivo* pig lung model.

501

502   In light of this, it is significant that our results suggest preferential localisation of *S. aureus*

503   in the ASM surrounding the tissue sections, as opposed to epithelial surface attachment,

504   and we did not observe the appearance of abscess-like structures. *S. aureus* can cause

505   lung abscess in humans – in fact it is one of the most common bacteria isolated from

506   abscesses (60) – but abscesses are almost never observed in people with CF (56, 57). A

507   specific Panton-Valentine Leukocidin positive strain of MRSA was associated with

508   invasive, cavitating lung lesions in a CF centre in the USA in the mid 2000s (61), but this

509   is unusual. Other than this specific outbreak, a literature search revealed only five cases

510   of abscess among people with CF, only two of which were associated with *S. aureus*: one

511   patient was co-colonized by *P. aeruginosa* and the other with *P. denitrificans* (34, 62). It

512   should be noted that abscess formation is associated with the presence of neutrophils,

513   our model uses post mortem tissue and, therefore, the effect of the host immune response

514   is not observable. In addition tissue samples in our model are taken only from the bronchi

515   wall and so may not capture abscess formation. However, given the rarity of clinical

516   evidence for invasive *S. aureus* infection in people with CF, induction of abscess formation

517   may not be clinically important in a CF model. Clinical observations are consistent with a

518   study in which mucus hypersecretion was induced in cultured primary nasal epithelia cells

519   to better mimic conditions in the CF lung: mucus presence led to *S. aureus* cells moving

520   away from the epithelial cell surface and growing in the mucus (25) – as observed in our

521   model.

522

Chronic infection phenotypes of *S. aureus* in EPVL. The tissue-associated subpopulation exhibited enhanced tolerance to flucloxacillin compared with standard susceptibility assay results. This is likely due to physiological cues from the lung environment and the appearance of a subpopulation of SCVs (11, 13, 63-65) but may also be influenced by the presence of biofilm structure matrix if it is present (which could usefully be explored in future work).

Small colony variants emerged once *S. aureus* isolates were passaged through the EPVL. The phenotypic development of SCVs has been linked to chronic CF infections (63, 64). The impact of SCVs on virulence and persistence is difficult to study *in vitro* as they rapidly revert to normal colony morphology when attempts are made to culture them *in vitro* (51) and usually requires the creation of artificially generated, stable SCVs which may not fully represent those generated by the *in vivo* environment(66). Notwithstanding these limitations, studies have linked the SCV phenotype with attenuated virulence (67) and a dampened host cytokine response (68, 69) – both changes consistent with adoption of persistence strategy. The ability of the *ex vivo* lung model to cue SCV emergence is likely to be a significant strength of the model, permitting a rapid means to generate this phenotype and allowing more extensive future research into the effects of SCVs. It will be important, however, to tease apart the relative contributions of the presence of tissue and the presence of sub-inhibitory levels of ampicillin on SCV emergence. Since completing this work, we have begun a more extensive investigation of methods to reduce the presence of endogenous bacteria from the lung tissue, and we have found that expedited access to lungs after slaughter allows us to obtain tissue which requires less rigorous control measures. Future experiments using EVPL with different or no antibiotic

547 supplementation will allow us to explore the impacts of tissue and antibiotic presence on

548 microbial physiology.

549

550 **Population heterogenicity of *S. aureus in vivo* and in EVPL**. The evidence outlined

551 above is consistent with *S. aureus* growing as phenotypically heterogeneous populations

552 in CF – comprising tissue-associated, biofilm-like aggregates and mucus-embedded

553 aggregates, with potential presence of SCVs. Persistence, antibiotic tolerance, gene

554 expression and ability to be cultured *in vitro* are likely to differ between these

555 subpopulations, and understanding the differences within heterogenous populations could

556 improve understanding of virulence mechanisms. If this is the case, the *ex vivo* pig lung

557 model will be valuable in future study for the generation of heterogenous populations that

558 are hard to reproduce in animal and traditional *in vitro* models.

559

560 **Strengths and limitations of the EVPL model.** Our data reinforce the notion that host

561 specific pathology is an important area of future study, with particular significance for *S.*

562 *aureus*. Modelling *S. aureus* infection, in any tissue other than human biopsy, is likely to

563 present differences and challenges. It is abundantly clear that both mouse and *in vitro*

564 models fail to capture key features of pathology observed from human clinical data that

565 are revealed by our EVPL model. Consequently, EVPL could fill an important gap in the

566 toolkit for answering crucial questions about the microbiology and clinical impact of *S.*

567 *aureus* in CF.

568

569 There are, of course, some areas where the model could be optimised for future use.

570 Primarily, variability in *S. aureus* bacterial load was considerable. We inoculated tissue

571 sections from single colonies, and not a standardised broth culture, as preliminary work

572 with *P. aeruginosa* in an earlier version of the model showed no significant variation in the

573 number of cells inoculated from single colonies, or the cell numbers recorded at 48 h (39).

574 Additionally, in CF there is unlikely to be a large burden of colonising bacteria (70). Given

575 the differences in the way that *P. aeruginosa* and *S. aureus* grow in the model, starting

576 inoculum may be a more significant determinant of the growth and survival of *S. aureus*

577 and standardising cell numbers could be important for future developments, for example

578 assessing the impact of antimicrobial agents on viable bacterial burden. More broadly,

579 better data on the variability in *S. aureus* aggregate size between foci of infection within

580 CF lungs, and between patients, would be useful for understanding *S. aureus* pathology.

581 In a study by Hirschhausen *et al.* (59), adaptive changes differed in patients infected with

582 the same *S. aureus* clonal lineage, indicating that individual host factors had an impact on

583 adaption. This is reminiscent of our results, which show significant variability between

584 lungs taken from different pigs (Fig 2).

585

586 We also stress, given the reported intraspecific phenotypic and genetic diversity of

587 bacteria within and between people with CF, and given observed differences in the growth

588 and localisation of a pair of isolates taken from stable infection and acute exacerbation

589 (Fig 2 and 3-4), future work could usefully explore a larger collection of isolates in more

590 depth.

591

592 **Conclusion.**

593 The *ex vivo* lung model is designed to maximise physicochemical similarity to chronically-

594 infected human CF airways. It is also high throughput and inexpensive, and because it

595 uses post-consumer waste from the meat industry, it presents no ethical concerns (38).

596 Our results from *S. aureus* infection of the *ex vivo* model reveal aspect of chronic CF

597 pathology which are not captured by existing "gold standard" animal models: aggregation

598 of bacterial cells associated with tissue but also (perhaps predominantly) in mucus; the

599 development of SCVs; and an increase in antibiotic tolerance. The potential preferential

600 binding of *S. aureus* to mucus, and lack of tissue invasion, is a phenomenon that may

601 have clinical relevance, especially given current questions about the role of *S. aureus* as

602 a CF pathogen and the consequences of trying to remove it.

603

604 **Author Contributions**

605 FH & ES conceived the study. ES optimised EVPL for the present work with *S. aureus*,

606 conducted experimental work, analysed data and drafted the manuscript. FH

607 developed the EVPL model and contributed to manuscript preparation. NEH

608 conducted experimental work (histological sample preparation and imaging),

609 completed statistical data analysis and contributed to manuscript preparation. AHH

610 and BCA conducted experimental work as part of student projects for the University of

611 Warwick's BSc(Hons) in Biomedical Science and MB ChB, respectively. MMH

612 contributed to the development of EVPL, conducted experimental work and edited the

613 manuscript. MATM contributed clinical isolates and associated data. ARS and MNH

614 contributed clinical context for the study goals and interpretations, and contributed to

615 manuscript preparation. All authors saw and approved the final manuscript draft.

616

617 **Conflicts of Interest**

618 The authors declare there are no conflicts of interest.

619

620 **Funding Information**

627

628 **Ethical approvals**

629 All methods were carried out in accordance with institutional and national guidelines and

630 regulations. Sample collection and protocols were approved by the Biomedical Research

631 Committee of Research Institute la Fe (reference 2014/0563). Initial diagnostic plates of

632 sputum samples were not stored and were discarded after strain isolation, and strains

633 were anonymized: thus, according to the provisions of article 24 of Royal Decree

634 1716/2011 on biomedical research, it was not necessary to request the declaration of

635 compliance with the organic law on data protection, nor informed consent.

636

637 **Acknowledgements**

647

648

649   References
650

651   1.   Ahlgren HG, Benedetti A, Landry JS, Bernier J, Matouk E, Radzioch D, et al. Clinical
652   outcomes associated with Staphylococcus aureus and Pseudomonas aeruginosa airway
653   infections in adult cystic fibrosis patients. BMC Pulm Med. 2015 Jun 21;15:67.
654   2.   Szaff M, Hoiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic
655   fibrosis. Acta Paediatr Scand. 1982 Sep;71(5):821-6.
656   3.   Cystic Fibrosis Foundation Patient Registry 2018 Annual Data Report. Cystic Fibrosis
657   Foundation, 2019.
658   4.   Hurley MN. Staphylococcus aureus in cystic fibrosis: problem bug or an innocent
659   bystander? Breathe (Sheff). 14. England2018. p. 87-90.
660   5.   Stone A, Quittell L, Zhou J, Alba L, Bhat M, DeCelie-Germana J, et al. Staphylococcus
661   aureus nasal colonization among pediatric cystic fibrosis patients and their household
662   contacts. Pediatr Infect Dis J. 2009 Oct;28(10):895-9.
663   6.   Fritz SA, Krauss MJ, Epplin EK, Burnham CA, Garbutt J, Dunne WM, et al. The natural
664   history of contemporary Staphylococcus aureus nasal colonization in community children.
665   Pediatr Infect Dis J. 2011 Apr;30(4):349-51.
666   7.   Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, et al.
667   Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic
668   fibrosis. Pediatr Pulmonol. 1999 Nov;28(5):321-8.
669   8.   Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD.
670   Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in
671   infants with cystic fibrosis. Pediatr Pulmonol. 1996 May;21(5):267-75.
672   9.   Limoli DH, Hoffman LR. Help, hinder, hide and harm: what can we learn from the
673   interactions between Pseudomonas aeruginosa and Staphylococcus aureus during
674   respiratory infections? Thorax. 2019 Feb 18.
675   10.   Goerke C, Wolz C. Regulatory and genomic plasticity of Staphylococcus aureus during
676   persistent colonization and infection. Int J Med Microbiol. 2004 Sep;294(2-3):195-202.
677   11.   Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, et al.
678   Staphylococcus aureus small-colony variants are independently associated with worse lung
679   disease in children with cystic fibrosis. Clin Infect Dis. 2013 Aug;57(3):384-91.
680   12.   Kahl BC, Duebbers A, Lubritz G, Haeberle J, Koch HG, Ritzerfeld B, et al. Population
681   dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis
682   patients during a 6-year prospective study. J Clin Microbiol. 2003 Sep;41(9):4424-7.
683   13.   Besier S, Smaczny C, von Mallinckrodt C, Krahl A, Ackermann H, Brade V, et al.
684   Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic
685   fibrosis lung disease. J Clin Microbiol. 2007 Jan;45(1):168-72.
686   14.   Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T, et al. Inflammatory responses
687   to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis. 2011
688   Sep;53(5):425-32.
689   15.   Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, et al. Impact of
690   Pseudomonas and Staphylococcus infection on inflammation and clinical status in young
691   children with cystic fibrosis. J Pediatr. 2009 Feb;154(2):183-8.
692   16.   Davis SD, Fordham LA, Brody AS, Noah TL, Retsch-Bogart GZ, Qaqish BF, et al.
693   Computed tomography reflects lower airway inflammation and tracks changes in early cystic
694   fibrosis. Am J Respir Crit Care Med. 2007 May 1;175(9):943-50.

695   17.   Granchelli AM, Adler FR, Keogh RH, Kartsonaki C, Cox DR, Liou TG. Microbial
696   Interactions in the Cystic Fibrosis Airway. J Clin Microbiol. 2018 Aug;56(8).
697   18.   Wong JK, Ranganathan SC, Hart E. Staphylococcus aureus in early cystic fibrosis lung
698   disease. Pediatr Pulmonol. 2013 Dec;48(12):1151-9.
699   19.   Ratjen F, Comes G, Paul K, Posselt HG, Wagner TO, Harms K. Effect of continuous
700   antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic
701   fibrosis. Pediatr Pulmonol. 2001 Jan;31(1):13-6.
702   20.   Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants
703   and young children with cystic fibrosis: a randomized controlled trial. J Pediatr. 2002
704   Mar;140(3):299-305.
705   21.   Smyth AR, Rosenfeld M. Prophylactic anti-staphylococcal antibiotics for cystic
706   fibrosis. Cochrane Database Syst Rev. 2017 Apr 18;4:Cd001912.
707   22.   Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a
708   receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A. 1995 Mar
709   28;92(7):3019-23.
710   23.   Schwab UE, Wold AE, Carson JL, Leigh MW, Cheng PW, Gilligan PH, et al. Increased
711   adherence of Staphylococcus aureus from cystic fibrosis lungs to airway epithelial cells. Am
712   Rev Respir Dis. 1993 Aug;148(2):365-9.
713   24.   McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Doring G, et al. Broadly
714   protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.
715   Science. 1999 May 28;284(5419):1523-7.
716   25.   Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Munker G, et al. Localization of
717   Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture
718   model of S. aureus adherence. Am J Respir Cell Mol Biol. 1998 Jul;19(1):83-91.
719   26.   Shuter J, Hatcher VB, Lowy FD. Staphylococcus aureus binding to human nasal
720   mucin. Infect Immun. 1996 Jan;64(1):310-8.
721   27.   Sanford BA, Thomas VL, Ramsay MA. Binding of staphylococci to mucus in vivo and in
722   vitro. Infect Immun. 1989 Dec;57(12):3735-42.
723   28.   Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis
724   pathogens. Int J Med Microbiol. 2010 Dec;300(8):584-93.
725   29.   Lavelle GM, White MM, Browne N, McElvaney NG, Reeves EP. Animal Models of
726   Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences. Biomed Res Int.
727   2016;2016:5258727.
728   30.   Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller BH. The relationship of
729   chronic mucin secretion to airway disease in normal and CFTR-deficient mice. Am J Respir
730   Cell Mol Biol. 1998 Dec;19(6):853-66.
731   31.   Cigana C, Bianconi I, Baldan R, De Simone M, Riva C, Sipione B, et al. Staphylococcus
732   aureus Impacts Pseudomonas aeruginosa Chronic Respiratory Disease in Murine Models. J
733   Infect Dis. 2018 Mar 5;217(6):933-42.
734   32.   Kuhajda I, Zarogoulidis K, Tsirgogianni K, Tsavlis D, Kioumis I, Kosmidis C, et al. Lung
735   abscess-etiology, diagnostic and treatment options. Ann Transl Med. 2015 Aug;3(13):183.
736   33.   Patradoon-Ho P, Fitzgerald DA. Lung abscess in children. Paediatr Respir Rev. 2007
737   Mar;8(1):77-84.
738   34.   Canny GJ, Marcotte JE, Levison H. Lung abscess in cystic fibrosis. Thorax. 1986
739   Mar;41(3):221-2.

740 35.   Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR. Rate of improvement
741 of CF life expectancy exceeds that of general population--observational death registration
742 study. J Cyst Fibros. 2014 Jul;13(4):410-5.
743 36.   Andersen DH. Therapy and prognosis of fibrocystic disease of the pancreas.
744 Pediatrics. 1949 Apr;3(4):406-17.
745 37.   Palmer KL, Aye LM, Whiteley M. Nutritional cues control Pseudomonas aeruginosa
746 multicellular behavior in cystic fibrosis sputum. J Bacteriol. 2007 Nov;189(22):8079-87.
747 38.   Harrison F, Diggle SP. An ex vivo lung model to study bronchioles infected with
748 Pseudomonas aeruginosa biofilms. Microbiology. 2016 Oct;162(10):1755-60.
749 39.   Harrison F, Muruli A, Higgins S, Diggle SP. Development of an ex vivo porcine lung
750 model for studying growth, virulence, and signaling of Pseudomonas aeruginosa. Infect
751 Immun. 2014 Aug;82(8):3312-23.
752 40.   Harrington   NE, Sweeney   E, Harrison F. Building a better biofilm - formation of *in
753 vivo* -like biofilm structures by P*seudomonas aeruginosa* in a porcine model of cystic
754 fibrosis lung infection. bioRxiv   8585972019.
755 41.   Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdts V. The pig: a model for
756 human infectious diseases. Trends Microbiol. 2012 Jan;20(1):50-7.
757 42.   Williams PP, Gallagher JE. Preparation and long-term cultivation of porcine tracheal
758 and lung organ cultures by alternate exposure to gaseous and liquid medium phases. In
759 Vitro. 1978 Aug;14(8):686-96.
760 43.   Martineau F, Picard FJ, Ke D, Paradis S, Roy PH, Ouellette M, et al. Development of a
761 PCR assay for identification of staphylococci at genus and species levels. J Clin Microbiol.
762 2001 Jul;39(7):2541-7.
763 44.   Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob
764 Chemother. 2001 Jul;48 Suppl 1:5-16.
765 45.   Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for
766 antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 1-2.
767 46.   Bergan T. Penicillins. Antibiot Chemother (1971). 1978;25:1-122.
768 47.   Vanhommerig E, Moons P, Pirici D, Lammens C, Hernalsteens JP, De Greve H, et al.
769 Comparison of biofilm formation between major clonal lineages of methicillin resistant
770 Staphylococcus aureus. PLoS One. 2014;9(8):e104561.
771 48.   Goerke C, Wolz C. Adaptation of Staphylococcus aureus to the cystic fibrosis lung. Int
772 J Med Microbiol. 2010 Dec;300(8):520-5.
773 49.   Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr
774 Opin Pulm Med. 2006 Nov;12(6):440-4.
775 50.   DePas WH, Starwalt-Lee R, Van Sambeek L, Ravindra Kumar S, Gradinaru V, Newman
776 DK. Exposing the Three-Dimensional Biogeography and Metabolic States of Pathogens in
777 Cystic Fibrosis Sputum via Hydrogel Embedding, Clearing, and rRNA Labeling. MBio. 2016
778 Sep 27;7(5).
779 51.   Kahl BC, Becker K, Loffler B. Clinical Significance and Pathogenesis of Staphylococcal
780 Small Colony Variants in Persistent Infections. Clin Microbiol Rev. 2016 Apr;29(2):401-27.
781 52.   Baltimore RS, Christie CD, Smith GJ. Immunohistopathologic localization of
782 Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the
783 pathogenesis of progressive lung deterioration. Am Rev Respir Dis. 1989 Dec;140(6):1650-
784 61.

785 53. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, et al.
786 Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr
787 Pulmonol. 2009 Jun;44(6):547-58.
788 54. Henderson AG, Ehre C, Button B, Abdullah LH, Cai LH, Leigh MW, et al. Cystic fibrosis
789 airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J Clin
790 Invest. 2014 Jul;124(7):3047-60.
791 55. Potts SB, Roggli VL, Spock A. Immunohistologic quantification of Pseudomonas
792 aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Pediatr Pathol Lab
793 Med. 1995 Sep-Oct;15(5):707-21.
794 56. de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R, Pare PD, et al. Progressive
795 damage on high resolution computed tomography despite stable lung function in cystic
796 fibrosis. Eur Respir J. 2004 Jan;23(1):93-7.
797 57. Dovey M, Wisseman CL, Roggli VL, Roomans GM, Shelburne JD, Spock A.
798 Ultrastructural morphology of the lung in cystic fibrosis. J Submicrosc Cytol Pathol. 1989
799 Jul;21(3):521-34.
800 58. Sawai T, Tomono K, Yanagihara K, Yamamoto Y, Kaku M, Hirakata Y, et al. Role of
801 coagulase in a murine model of hematogenous pulmonary infection induced by intravenous
802 injection of Staphylococcus aureus enmeshed in agar beads. Infect Immun. 1997
803 Feb;65(2):466-71.
804 59. Hirschhausen N, Block D, Bianconi I, Bragonzi A, Birtel J, Lee JC, et al. Extended
805 Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation.
806 Int J Med Microbiol. 2013 Dec;303(8):685-92.
807 60. Madhani K, McGrath E, Guglani L. A 10-year retrospective review of pediatric lung
808 abscesses from a single center. Ann Thorac Med. 2016 Jul-Sep;11(3):191-6.
809 61. Elizur A, Orscheln RC, Ferkol TW, Atkinson JJ, Dunne WM, Jr., Buller RS, et al. Panton-
810 Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in
811 patients with cystic fibrosis. Chest. 2007 Jun;131(6):1718-25.
812 62. Lester LA, Egge A, Hubbard VS, Di Sant' Agnese PA. Aspiration and lung abscess in
813 cystic fibrosis. Am Rev Respir Dis. 1983 Jun;127(6):786-7.
814 63. Goss CH, Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis.
815 J Cyst Fibros. 2011 Sep;10(5):298-306.
816 64. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, et al. Small
817 colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent
818 infections. Nat Rev Microbiol. 2006 Apr;4(4):295-305.
819 65. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug
820 Discov. 2003 Feb;2(2):114-22.
821 66. Kriegeskorte A, Grubmuller S, Huber C, Kahl BC, von Eiff C, Proctor RA, et al.
822 Staphylococcus aureus small colony variants show common metabolic features in central
823 metabolism irrespective of the underlying auxotrophism. Front Cell Infect Microbiol.
824 2014;4:141.
825 67. Sifri CD, Baresch-Bernal A, Calderwood SB, von Eiff C. Virulence of Staphylococcus
826 aureus small colony variants in the Caenorhabditis elegans infection model. Infect Immun.
827 2006 Feb;74(2):1091-6.
828 68. Ou JJ, Drilling AJ, Cooksley C, Bassiouni A, Kidd SP, Psaltis AJ, et al. Reduced Innate
829 Immune Response to a Staphylococcus aureus Small Colony Variant Compared to Its Wild-
830 Type Parent Strain. Front Cell Infect Microbiol. 2016;6:187.

831 69.   Tuchscherr L, Medina E, Hussain M, Volker W, Heitmann V, Niemann S, et al.
832 Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host
833 immune response and establish a chronic infection. EMBO Mol Med. 2011 Mar;3(3):129-41.
834 70.   Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev.
835 2010 Apr;23(2):299-323.
836
837

838 **Figures and Tables**

841 **Figure 1. Recovery of *Staphylococcus aureus* following 48 H in the *ex vivo* pig lung model (EVPL).** Each *S. aureus* isolate was

842 inoculated into four replica bronchiolar sections of tissue (a single pair of lungs was used on each of 3 separate days).

843 Uninfected tissue was used as a control. Samples were destructively sampled at 48 h post infection. *S. aureus* bacterial load

844 was recovered on selective media (MSA) and is measured as total colony forming units per lung sample (Total CFU). Solid

845 lines indicate median values and the limit of detection is shown as a dashed line, no colonies were observed on plates where

846 data is at the limit of detection. USA300 is used as a representative control strain known to form biofilm. Clinical isolates

847 were supplied by the Instituto de Investigación Sanitaria La Fe (Table S1, supplementary material) and numbers are

848 designated as supplied. Analysis of untransformed data by ANOVA showed statistically significant differences in the bacterial

849 load attained by the different strains ($F_{7,32} = 1.90$, $p = 0.02$).

Figure 2. Recovery of an exacerbation vs chronic CF isolate of *Staphylococcus aureus* in the *ex vivo* pig lung model EVPL. *S. aureus* isolates were inoculated into six replica bronchiolar sections of tissue from each of three independent pairs of lungs, and samples were destructively sampled at 48 h and 7 days post infection by removing the tissue section from surrounding ASM and bead beating to release adherent bacteria. *S. aureus* bacterial load was recovered on selective media (MSA) and measured as total colony forming units per tissue sample (CFU). Triplicate lungs are indicated by point shape, and lines represent mean values. The limit of detection is shown as a dashed line. Colony counts on MSA, for uninfected tissue, were not recorded above the detectable limit at 48 H demonstrating that there was no inherent *S. aureus* presence in the lung tissue prior to inoculation. USA300 is used as a representative control strain. CF isolates supplied by the Instituto de Investigación Sanitaria La Fe and numbers are designated as supplied. ANOVA conducted on log-transformed data revealed significant main effects of strain ($F_{2,40}$ = 12.0, *p* < 0.001), lung ($F_{2,40}$ = 6.03, *p* = 0.005) and day, and a significant interaction between lung and strain ($F_{4,40}$ = 2.62, *p* = 0.049). There was no significant interaction between day and lung ($F_{2,40}$ = 9.5, *p* = 0.110) or day and strain ($F_{2,40}$ = 1.73, *p* = 0.190).

Figure 3. H & E stain of representative lungs at day 2.
Uninfected control (a,b) and 48 h post inoculation with FQ151 (c, d), FQ184 (e, f) or USA300 (g, h). x20 magnification (a, c, e and g). Highlighted area of interest (rectangle) is shown at x100 magnification (b, d, f and h). Scale bars represent 50μm and 10μm accordingly. Cocci shaped cells are present in all inoculated tissue at x 100 (d, f and h) but not uninfected control (b). Disruption to bronchiole tissue is also evident in all infected samples (*), less extensive for FQ184 (e), a strain taken during acute exacerbation, but more marked for USA300 (g) and not seen in uninoculated control (a). Arrows indicate the presence of rod shaped bacterial cells in both uninfected (b) and inoculated (f) samples, suggesting the presence of endogenous lung species.

870

871

872

873

Figure 4. H & E stain of representative lungs at day 7.
Uninfected control (a,b) and 7 days post inoculation with FQ151 (c, d) FQ184 (e, f) and USA300 (g,h). x20 magnification (a,c,e and g). Highlighted area of interest (rectangle) is then shown at x100 magnification (b, d, f and h). Scale bars represent 50µm and 10µm accordingly. Clusters of cocci shaped cells are present at or near tissue airway interface for all inoculated tissue at x 100 (d, f and h) but not uninfected control (b).

874

875

876

877

878

879

880   a)

881

882   b)

883

884   **Figure 5. Location of *Staphylococcus aureus* in *ex vivo* pig lung (EVPL) model 48 h and 7 days: CFU and proportion of CFU**

885   **recovered from Artificial Sputum Media (ASM) vs. tissue.** *S. aureus* isolates were inoculated into six replica bronchiolar

886   sections of tissue from each of three independent pairs of lungs, and samples were destructively sampled at 48 h and 7 days

887   post infection. Aliquots of the ASM surrounding each sampled piece of tissue were also assessed for bacterial load. USA300

888   was used as representative control strain and an uninfected lung used as a negative control. Clinical isolates supplied by the

889   Instituto de Investigación Sanitaria La Fe and numbers are designated as supplied. **(a)** *S. aureus* cell counts recovered on MSA

890   agar from EPVL at 48 h and 7 days. Bacterial load measured as total colony forming units per tissue, surrounding ASM or

891   total sample (CFU). Counts were taken from triplicate lungs, indicated by point shape. Non-parametric Kruskal Wallis tests

892 were used to test for differences in the proportion of bacteria in the surrounding ASM at 48 h and 7 days. Increases in

893 proportional growth in ASM were found for strains FQ128 (Chi-squared = 7.44, p =0.006, df = 1), FQ140 (Chi-squared = 11, p

894 < 0.001, df = 1), FQ151 (Chi-squared = 7.1, p =0.008, df = 1) and USA300 (Chi-squared = 12.3, p < 0.001, df = 1). FQ142

895 showed no significant increase in ASM proportion (Chi-squared = 1.2, *p* = 0.22, df =1). **(b)** Proportion of total CFU recovered

896 from tissue vs surrounding ASM at 48 h and 7 days. Line shows equal CFU in ASM and tissue, for reference. Minimum limit

897 of detection 4.3 x 10^1. Linear models on log-log transformed data showed a significant correlation between growth

898 associated with tissue and growth in surrounding ASM at both time points. (Full details of ANOVA results in Supplementary

899 information, R^2adj for models testing for effects of lung, strain, CFU lung and strain*CFU lung on CFU in ASM were 0.50 for

900 48 h data and 0.36 for day 7 data.

a

b

Time (h) since abx exposure	ATCC29213 survival (CFU) following flucloxacillin challenge (mg/l)		
	0mg/L	0.25mg/L	5mg/L
0 (pre-dose)	5.46E+06	NA	NA
4	1.38E+07	1.01E+07	4.64E+06
24	1.41E+06	1.45E+06	2.25E+06

Time (h) since abx exposure	FQ128 survival (CFU) following flucloxacillin challenge (mg/L)		
	0mg/L	0.25mg/L	5mg/L
0 (pre-dose)	3.71E+06	NA	NA
4	5.23E+06	1.70E+06	1.11E+06
24	5.65E+05	6.87E+05	3.84E+04

Time (h) since abx exposure	FQ142 survival (CFU) following flucloxacillin challenge (mg/L)		
	0mg/L	0.25mg/L	5mg/L
0 (pre-dose)	8.58E+04	NA	NA
4	7.81E+04	5.23E+03	3.04E+04
24	6.14E+05	9.97E+04	4.30E+01

903 **Figure 6 recovery of *S. aureus* clinical isolates from EPVL following flucloxacillin challenge.** Each *S. aureus* isolate was

904 inoculated into replica bronchiolar sections of tissue from the same pair of lungs, and incubated as previously described for

905 48 h. Four replica samples were processed for counting of bacterial load, prior to antibiotic challenge (0 h, pre-dose).

906 Remaining samples were moved to ASM containing either no antibiotic (●), 0.25mg/l (▲) or 5mg/l (◊)flucloxacillin and

907 incubated for 4 or 24 h. Uninfected tissue pieces were used as control and processed as infected replica, no colonies were

908 observed on recovery plates for uninfected controls. Lines represent mean bacterial load. All isolates were classified as

909 sensitive by standard antibiotic susceptibility testing (MIC <0.0625mg/l). Bactericidal activity, (>3log$_{10}$ in CFU) was only

910 observed against FQ142 when challenged with 5mg/l flucloxacillin for 24 h (Fig 6b, highlighted). Antibiotic dose had no

911 significant effect for ATCC29213 (ANOVA, $f_{2,21}$=0.2 *p*=0.8) for clinical strains there was an overall effect of dose: ANOVA,

912 $f_{2,21}$=5.8, *p*=0.01 and $f_{2,21}$=7.5, *p*= 0.004 for FQ128 and FQ142 respectively. However post hoc analysis revealed there was no

913 significance for either strain when exposed to 0.25mg/l flucloxacillin (FQ128, *p*=0.8 and FQ142, *p*=0.2).

Supplementary data.

916 **Table S1. Clinical *Staphylococcus aureus* strains isolated from sputum samples from individuals with CF.** Samples and

917 health data collected and donated by the Instituto de Investigación Sanitaria La Fe, Valencia. Sample numbers are designated

918 as supplied.

| Sample	Patient Identifier	Patient age at sampling	Exacerbation	Biofilm	MRSA	Other microorganisms isolated
FQ16	51	21	No	Strong	No	*Pseudomonas aeruginosa, Aspergillus fumigatus*
FQ203	51	22	No	Moderate	No	*Pseudomonas aeruginosa, Burkholderia cepacia*
FQ22	21	17	No	Moderate	No	no
FQ91	80	7	No	Weak	No	no
FQ151	80	8	No	Moderate	Yes	no
FQ233	80	8	Mild	Moderate	Yes	no
FQ128	40	20	No	Strong	No	*Candida albicans*
FQ220	40	21	Yes	Moderate	No	*Candida albicans*
FQ140	99	8	No	Moderate	Yes	*Pseudomonas aeruginosa, Candida albicans*
FQ184	99	9	Severe	Moderate	Yes	*Pseudomonas aeruginosa*
FQ210	99	9	No	None	Yes	*Pseudomonas aeruginosa, Candida albicans, Haemophilus influenzae*
FQ142	25	13	No	None	No	*Candida albicans, Aspergillus fumigatus*
FQ228	25	14	Severe	None	No	*Candida albicans*
FQ118	70	14	No	Strong	No	no
FQ153	70	15	No	Strong	No	*Candida albicans*
FQ139	47	12	No	Moderate	No	*Aspergillus fumigatus*
FQ160	48	9	No	Weak	No	no
FQ224	48	10	No	Weak	No	no

920

921

922

923

924

925

Figure S1. H & E stain of representative lungs at day 2.
Uninfected control (a,b) and 48 h post inoculation with FQ151 (c, d), FQ184 (e, f)or USA300 (g, h). x20 magnification (a, c, e and g). Highlighted area of interest (rectangle) is then shown at x100 magnification (b, d, f and h). Scale bars represent 50μm and 10μm accordingly. Cocci shaped cells are present in all inoculated tissue at x 100 (d, f and h) but not uninfected control (b).

926

Figure S2. H & E stain of representative lungs at day 2.
Uninfected control (a,b) and 48 h post inoculation with FQ151 (c, d), FQ184 (e, f)or USA300 (g, h). x20 magnification (a, c, e and g). Highlighted area of interest (rectangle) is then shown at x100 magnification (b, d, f and h). Scale bars represent 50μm and 10μm accordingly. Cocci shaped cells are present in all inoculated tissue at x 100 (d, f and h) but not uninfected control (b).

927

Figure S3. H & E stain of representative lungs at day 7.
Uninfected control (a,b) and 7 days post inoculation with FQ151 (c, d) FQ184 (e, f) and USA300 (g,h). x20 magnification (a,c,e and g). Highlighted area of interest (rectangle) is then shown at x100 magnification (b, d, f and h).   Scale bars represent 50μm and 10μm accordingly. Clusters of cocci shaped cells are present at or near tissue airway interface for all inoculated tissue at x 100 (d, f and h) but not uninfected control (b).

928
929

Figure S4. H & E stain of representative lungs at day 7.
Uninfected control (a,b) and 7 days post inoculation with FQ151 (c, d) FQ184 (e, f) and USA300 (g,h). x20 magnification (a,c,e and g). Highlighted area of interest (rectangle) is then shown at x100 magnification (b, d, f and h). Scale bars represent 50µm and 10µm accordingly. Clusters of cocci shaped cells are present at or near tissue airway interface for all inoculated tissue at x 100 (d, f and h) but not uninfected control (b).

930
931
932

Figure S5. Gram stain of ASM samples surrounding lung at 7 day post inoculation in EPVL.

Uninfected control (a,) and 7 day post inoculation with USA300LAC (b), FQ128 (c) FQ140 (d), FQ142 (e) or FQ151 (f) magnification x100, scale bar represents 10μm. Aggregations of gram positive cocci, are seen in infected samples (b-f) but not uninfected control. Larger aggregates are observed in biofilm forming strains (b,c, d and f). Tissue and endogenous or contaminate bacteria are visible (but poorly stained) in uninfected control.

933
934
935

USA300LAC   FQ128   FQ140   FQ142   FQ151

Fig S6. Appearance of SCV on MSA plates. Samples taken from lung homogenate (top line) or surrounding ASM (bottom line) at 7 days post inoculation and incubated for 24 H at 37ºC in 5% CO_2 and a further 48 H in ambient conditions. Red arrows indicate typical SCV, selected and identified by catalase and coagulase tests and by PCR (Table S2).

Table S2. Identification of Small Colony Variants (SCVs). Catalase and coagulase result and colony identity as confirmed by 16S sequence. Samples were taken from lung homogenate or surrounding Artificial Sputum Media (ASM) at 7 days post inoculation and grown on MSA plates for 24 h at 37 °C in 5% CO_2 and a further 48 h in ambient conditions. SCVs were selected as shown in Fig S1 and all confirmed with *Staphylococcus* specific primers prior to sequencing of the 16S-23S intergenic spacer.

Strain originally inoculated	Diameter of small colony identified (% WT)	Coagulase	Catalase	16S sequence identity
USA300	27	+	+	*S. aureus*
USA300	32	+	+	*S. aureus*
FQ128	31	+	+	*S. aureus*
FQ128	23	+	+	*S. aureus*
FQ140	26	Weak	+	*S. aureus*
FQ140	25	Weak	+	*S. aureus*
FQ142	43	+	+	*S. aureus*
FQ142	43	+	+	*S. aureus*
FQ151	40	Weak	+	*S. aureus*
FQ151	31	Weak	+	*S. aureus*